Table 1.
Baseline characteristics.
| Characteristic | Daratumumab and Durvalumab |
|---|---|
| n = 18 | |
| Age, years; median (range) | 65.5 (40–75) |
| Male sex, n (%) | 7 (38.9) |
| ECOG performance status, n (%) | |
| - 0 | 12 (66.7) |
| - 1 | 5 (27.8) |
| - 2 | 1 (5.6) |
| - 3 | 0 |
| ISS stage at entry, n (%) | |
| - Stage I | 1 (5.6) |
| - Stage II | 5 (27.8) |
| - Stage III | 4 (22.2) |
| - Unknown | 8 (44.4) |
| M-protein, n (%) | |
| - IgA kappa | 4 (22.2) |
| - IgG kappa | 9 (50.0) |
| - IgG lambda | 3 (16.7) |
| - FLC lambda | 2 (11.1) |
| FISH analysis on isolated plasma cells, n (%) | 8 (44.4) |
| High risk cytogenetic abnormalities, n (%) | |
| - t(4;14) | Unknown |
| - del(17p) | 2 (25) |
| - t(14;16) | Unknown |
| - amp(1q) | 1 (12.5) |
| - del(13q) | 2 (25) |
| Prior lines of treatment, median (range) | 5 (3–16) |
| Prior IMiD agent, n (%) | |
| - Thalidomide | 5 (27.8) |
| - Lenalidomide | 18 (100) |
| - Pomalidomide | 14 (77.8) |
| Prior PI, n (%) | |
| - Bortezomib | 18 (100) |
| - Carfilzomib | 8 (44.4) |
| - Ixazomib | 0 |
| Prior alkylating agents, n (%) | |
| - Cyclophosphamide | 12 (66.7) |
| - Melphalan | 15 (83.3) |
| Prior monoclonal antibodies, n (%) | |
| - Daratumumab | 18 (100) |
| - Elotuzumab | 1 (5.6) |
| Prior autologous stem cell transplantation, n (%) | 15 (83.3) |
| Most recent daratumumab-containing regimen, n (%) | |
| - Daratumumab monotherapy | 5 |
| - Daratumumab + PI | 3 |
| - Daratumumab + IMiD agent | 10 |
| Best response to prior daratumumab-containing regimen, n (%) | |
| - CR | 0 |
| - VGPR | 3 (16.7) |
| - PR | 7 (38.9) |
| - MR | 2 (11.1) |
| - SD | 3 (16.7) |
| - PD | 2 (11.1) |
| - Unknown | 1 (5.6) |
| Creatinine clearance at entry, n (%) | |
| - ≥60 mL/min | 14 (77.8) |
| - 30–60 mL/min | 3 (16.7) |
| - <30 mL/min | 1 (5.6) |
| Platelet count at entry, n (%) | |
| - ≥150 × 109/L | 13 (72.2) |
| - <150 × 109/L | 5 (27.8) |
| LDH at entry, n (%) | |
| - Normal | 14 (77.8) |
| - Elevated | 4 (22.2) |
Abbreviations: ECOG, Eastern Cooperative Oncology Group; ISS, International Staging System; IMiD, immunomodulatory drug; PI, proteasome inhibitor; CR, complete remission; VGPR, very good partial response; PR, partial response; MR, minimal response; SD, stable disease; PD, progressive disease.